Document Detail


Medical management of urinary stone disease.
MedLine Citation:
PMID:  17516875     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Kidney stones occur in approximately 10% of patients in their lifetimes, and > 10 crystal types have been reported in the literature. After treatment, a subset of these patients will have recurrent calculi, leading to significant morbidity and potential for serious chronic renal disease. Detailed metabolic evaluation is indicated in patients at high risk for stone recurrence, as a reversible metabolic abnormality can be identified in > 90% of them. Once the patient's underlying physicochemical and physiologic derangements are defined, targeted medical therapy can be initiated in order to prevent growth of pre-existing stones and new stone formation. In this report, the author provides a comprehensive review of the presently available selective and nonselective pharmacologic treatments for stones. Several exciting investigational pharmaceutical agents for kidney stone prevention are also discussed. Although many of these agents are effective, there remain clinical scenarios in which existing medicines are insufficient.
Authors:
Sangtae Park
Related Documents :
1955135 - Occult microlithiasis in 'idiopathic' acute pancreatitis: prevention of relapses by cho...
7377965 - Oral cholecystography in assessment of acute abdominal pain.
8474265 - Urolithiasis in pediatric patients.
1154265 - Adenomyomatosis of the gallbladder.
24355635 - Pulmonary hypertension in chronic lung diseases.
14558885 - Benefits of early enteral nutrition with glutamine and probiotics in brain injury patie...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  8     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2007 Jun 
Date Detail:
Created Date:  2007-05-22     Completed Date:  2007-06-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  1117-25     Citation Subset:  IM    
Affiliation:
Department of Urology, University of Washington Medical Center, 1959 NE Pacific Ave., Box 356510, Seattle, WA 98195, USA. spark1@u.washington.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Crystallization
Drug Delivery Systems*
Humans
Kidney Calculi / diagnosis,  drug therapy*,  etiology,  physiopathology,  prevention & control
Metabolic Diseases
Prevalence
Recurrence
Risk Factors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple s...
Next Document:  Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hem...